S-多沙唑嗪 | 104874-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: S-多沙唑嗪
• 中文别名: 3-吖丁啶羧酸,1-(2-硝基苯基)-,甲基酯；S-多沙唑嗪-D8
• 英文名称: (S)-doxazosin
• 英文别名: Doxazosin, (S)-；[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methanone
• CAS: 104874-86-4
• 化学式: C₂₃H₂₅N₅O₅
• 分子量: 451.482
• InChiKey: RUZYUOTYCVRMRZ-FQEVSTJZSA-N

物化性质

• 沸点：
  718.0±70.0 °C(Predicted)
• 密度：
  1.371±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1,4-苯并二氧六环-2-甲酸乙酯 在 盐酸 、 sodium hydroxide 、 氯化亚砜 、 esterase from Serracia marcescens 、 碳酸氢钠 、 potassium carbonate 作用下， 以 甲醇 、 氘代氯仿 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 正丁醇 为溶剂， 反应 29.5h， 生成 S-多沙唑嗪
  参考文献：
  名称：

  Practical chemical and enzymatic technologies for (S)-1,4-benzodioxan-2-carboxypiperizine intermediate in the synthesis of (S)-doxazosin mesylate

  摘要：

  (S)-1,4-Benzodioxan-2-carboxypiperazine (S)-2, the key chiral intermediate for the synthesis of (S)-doxazosin, was prepared utilizing two approaches: (i) enzymatic resolution of ethyl 1,4-benzodioxan-2-carboxylate with an esterase (Serratia) followed by an-de formation; (ii) direct resolution of 1,4-benzodioxan-2-carboxypiperazine 2 with D-tartaric acid. An efficient process for the conversion of (S)-2 to (S)-doxazosin mesylate was developed (80% yield, 99.9% e.e.). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00368-8

文献信息

• AROMATIC AMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICAL USES OF BOTH
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813603A1

  公开（公告）日：2007-08-01

  A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group', an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group; M1 is a single bond, a C1-4 alkylene group or the like Y is N or CRF (in the formula, RF represents a hydrogen atom, a C1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  本发明提供了具有V2受体激动作用的芳香酰胺衍生物，可用作治疗或预防尿崩症、夜尿症、夜间遗尿、膀胱过度活跃或类似疾病的药物，并由通式（I）表示： 其中R1代表氢原子或可能具有取代基的C1-6烷基基团，R2是氢原子或C1-6烷基基团，R3是氢原子、C1-6烷基基团或类似物，R4、R5和R6独立地是氢原子、卤原子或类似物，R7是氢原子、可能具有取代基的杂环基团、C3-8环烷基团、可能具有取代基的氨基团或可能具有取代基的C1-6烷氧基团；M1是单键、C1-4烷基烃基团或类似物，Y是N或CRF（在该式中，RF代表氢原子、C1-6烷基基团或类似物），或其药学上可接受的盐，或其前药，或包含其的药物组合物和药物用途。
• UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1867639A1

  公开（公告）日：2007-12-19

  Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group, an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group, M1 is a single bond, a C1-4 alkylene group or the like, Y is N or CRF (in the formula, and RF represents a hydrogen atom, a C1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  以下一般公式（I）所代表的尿素衍生物，具有V2受体的激动作用，可用作治疗或预防尿崩症、夜尿、夜间遗尿、膀胱过度活动等药物。在公式中，R1代表氢原子或可能具有取代基团的C1-6烷基；R2是氢原子或C1-6烷基；R3是氢原子、C1-6烷基或其他基团；R4、R5和R6独立地是氢原子、卤素原子或其他基团；R7是氢原子、可能具有取代基团的杂环烷基、C3-8环烷基、可能具有取代基团的氨基或可能具有取代基团的C1-6烷氧基；M1是单键、C1-4烷基或其他基团；Y是N或CRF（在公式中，RF代表氢原子、C1-6烷基或其他基团），或其药学上可接受的盐、前药、包含相同成分的药物组合物及其药用。
• Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
  申请人：Boehringer Ingelheim Pharma GmbH & CO. KG

  公开号：US20030225079A1

  公开（公告）日：2003-12-04

  The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

  本发明涉及使用特定的EGF受体拮抗剂制备用于预防和/或治疗良性前列腺增生和/或前列腺肥大的药物组合物，一种治疗或预防良性前列腺增生/前列腺肥大的方法，包括在此处描述的(A)、(B)或(C)组的EGF受体拮抗剂的给药，可选择与已知的治疗良性前列腺增生/前列腺肥大的化合物联合使用，以及相关的药物组合物。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
  申请人：Yokoyama Kenji

  公开号：US20070232594A1

  公开（公告）日：2007-10-04

  A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group; M 1 is a single bond, a C 1-4 alkylene group or the like Y is N or CR F (in the formula, R F represents a hydrogen atom, a C 1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  本发明提供了具有V2受体激动作用的芳香酰胺衍生物，可用作治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等药物，其通式表示为（I）：其中R1表示氢原子或C1-6烷基，可以有取代基，R2表示氢原子或C1-6烷基，R3表示氢原子、C1-6烷基或类似物，R4、R5和R6分别表示氢原子、卤原子或类似物，R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或C1-6烷氧基；M1表示单键、C1-4烷基等，Y表示N或CRF（在公式中，RF表示氢原子、C1-6烷基或类似物的药物可接受的盐，或其前药，或包含它的制药组合物和制药用途）。